menu Search
Imbruvica

Imbruvica Overdosage

ibrutinib

Manufacturer:

Catalent CTS

Distributor:

Johnson & Johnson
Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Full Prescribing Info
Overdosage
Symptoms and signs: There are limited data on the effects of Ibrutinib (Imbruvica) overdose. No Maximum Tolerated Dose was reached in the phase 1 study in which patients received up to 12.5 mg/kg/day (1,400 mg/day). In a separate study, one healthy subject who received a dose of 1680 mg experienced reversible grade 4 hepatic enzyme increases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)]. There is no specific antidote for Ibrutinib (Imbruvica). Patients who ingested more than the recommended dose should be closely monitored and given appropriate supportive treatment.